THE CHALLENGE OF CANCER-RELATED THROMBOEMBOLIC DISEASE: CAN WE BETTER PREDICT THE RISK
Ouvert
Mis à jour le 10/01/2024
Autres (toutes tumeurs)
Informations générales
  • Titre abrégé

    PROSPECT

  • NCT

    NCT02785757

  • N° Eudract

    2013-A00065-40

  • Phase de l'essai
    • Non applicable
Promoteur
  • Type de promoteur

    Académique / Institutionnel

  • Nom du promoteur

    HCL

Critères d'inclusion
  • Adult patients (> 18 yo) of both sexes with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy " Subjects having signed Informed Consent prior to initiation of any study procedure " Covered by a Health System
Critères d'exclusion
  • Known bleeding or thrombophilia disorders " ECOG performance status* e" 3 " Patient immobilized " Confirmed venous thromboembolism in the last 12 months " Active bleeding or bleedings in the last 4 weeks requiring hospitalization, transfusion, or surgical intervention " Anticoagulant or antiplatelet therapy at the moment of inclusion " Severe hepatic insufficiency " Life expectancy of less than 3 months " Pregnancy
Centre investigateur 1
  • Nom du centre

    HCL - Hôpital Edouard Herriot
    Lyon

  • Contact Investigateur

  • Nom

    Catherine LOMBARD

  • Contact ARC/TER/IRC

  • Nom

    Estelle MONDILLON

  • Email

    estelle.mondillon@chu-lyon.fr

Centre investigateur 2
  • Nom du centre

    Centre Léon Bérard
    Lyon

  • Contact Investigateur

  • Nom

    Dr. Philippe CASSIER

  • Autre contact

    Dr DESSEIGNE Françoise ; Pr RAY-COQUARD Isabelle ; Dr TREDAN Olivier ; Dr DE LA FOUCHARDIERE Christelle ; Dr FAYETTE Jérôme ; Dr HEUDEL Pierre Etienne ; Dr PEROL Maurice ; Dr SARABI Matthieu ;

  • Contact ARC/TER/IRC

  • Nom

    Mme Sandrine GUILLEMIN